Do not stop or change your medication without speaking to a pharmacist or healthcare professional.

Recalls / PICATO (ingenol mebutate gel, 0.015% and 0.05%) - Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer

PICATO (ingenol mebutate gel, 0.015% and 0.05%) - Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer

Drugs · Last updated 2020-10-27

Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.

See affected DINs and lot numbers on Health Canada ↗

Why it was recalled

Product safety

Source

Other Recent Recalls

PDP-DIPHENHYDRAMINE

PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)

Type II2026-11-09

Moderate health risk

Unauthorized injectable peptide and non-peptide drugs

Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs

2026-11-06

ANTICOAGULANT SODIUM CITRATE SOLUTION, USP

ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks

2026-11-03

Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.